# PBE (Invesco Biotechnology & Genome ETF)

Invesco · Thematic ETFs · data as of Sep 11, 2026

PBE holds 32 stocks, and 70% of its weight is outside the S&P 500.

## Key facts

- PBE, already in the S&P 500: 30.1%, as of Sep 11, 2026.
- PBE, active share vs the S&P 500: 99.0%, as of Sep 11, 2026.
- PBE, top ten holdings: 45.9%, as of Sep 11, 2026.
- PBE, total return, 1 year: +32.5%, as of Sep 11, 2026.
- PBE, net assets: $247m (SEC filing, whole fund, as filed for Apr 30, 2026).
- PBE, expense ratio: 0.59% (485BPOS XBRL, Aug 27, 2026).

## PBE over each window to Sep 11, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | +11.5% | +3.3% | +8.2 pts | +12.3 pts |
| 6 months | +23.3% | +16.0% | +7.2 pts | +2.6 pts |
| 1 year | +32.5% | +17.5% | +15.0 pts | +9.6 pts |
| 3 years | +56.6% | +77.9% | −21.2 pts | −38.4 pts |
| Since launch | +479.9% | +804.4% | −324.5 pts | −1194.0 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Biotech and genomics | ETFIQ, editorial |
| Launched | Jan 4, 2010 | ETFIQ |
| Already in the S&P 500, by weight | 30.1% | ETFIQ |
| Active share vs the S&P 500 | 99.0% | ETFIQ |
| Already in the Nasdaq-100, by weight | 19.7% | ETFIQ |
| Active share vs the Nasdaq-100 | 97.7% | ETFIQ |
| Top ten holdings weight | 45.9% | ETFIQ |
| Holdings | 32 | ETFIQ |
| Holdings as of | Sep 10, 2026 | the issuer’s daily file |
| Top holdings | Biogen Inc 5.2%, Gilead Sciences Inc 5.2%, Natera Inc 5.1%, Regeneron Pharmaceuticals Inc 5.0%, Royalty Pharma PLC 5.0%, Vertex Pharmaceuticals Inc 4.9%, Illumina Inc 4.7%, Amgen Inc 4.6%, Sarepta Therapeutics Inc 3.1%, Neurocrine Biosciences Inc 3.0% | ETFIQ |
| Net assets | $247m | SEC filing, whole fund, as filed for Apr 30, 2026 |
| Below its all-time high | −5.9% | ETFIQ |
| Expense ratio | 0.59% | 485BPOS XBRL, Aug 27, 2026 |
| Fee for the part that differs from the S&P 500, active expense ratio | 0.60% | ETFIQ |
| Closest funds by holdings overlap | FBT 52%, BBH 43%, IBBQ 38%, BBP 34%, GNOM 29% | ETFIQ |

## Questions

### How much of PBE is in S&P 500 companies?

By its holdings published by its issuer for Sep 10, 2026, 30% of PBE by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different.

### What does PBE hold?

32 positions as published by its issuer for Sep 10, 2026, with the top ten at 46% of the fund. The largest are Biogen Inc at 5.2%, Gilead Sciences Inc at 5.2%, Natera Inc at 5.1%.

### Has PBE beaten the S&P 500?

Over the year to Sep 11, 2026 PBE returned +32.5% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 15.0 points.

### What does PBE cost?

The prospectus expense ratio is 0.59% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.60%.


## Cite this page

ETFIQ, PBE, data as of Sep 11, 2026. https://etfiq.com/funds/PBE
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/PBE  ·  JSON: https://etfiq.com/funds/PBE.json